Müllerian inhibiting substance/anti-Müllerian hormone: A potential therapeutic agent for human ovarian and other cancers

Future Oncology

Volumn 6, Issue 3, 2010, Pages 391-405

  MacLaughlin, David T ^a   Donahoe, Patricia K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anti M llerian hormone; M llerian Inhibiting Substance; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOCHROME P450 17; CYTOTOXIC AGENT; DOXORUBICIN; HORMONE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUELLERIAN INHIBITING FACTOR; PACLITAXEL; TRANSCRIPTION FACTOR SOX9; TUMOR NECROSIS FACTOR ALPHA; WT1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CELL PROLIFERATION; DRUG DESIGN; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; HORMONE INHIBITION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW;

ANIMALS; ANTI-MULLERIAN HORMONE; FEMALE; HUMANS; NEOPLASMS; OVARIAN NEOPLASMS;

EID: 77949429032     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.172     Document Type: Review

References (122)

1. Love RR, Philips J: Oophorectomy for breast cancer: history revisited. J. Natl Cancer Inst. 94(19), 1433-1434 (2002).
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M: Cancer statistics. J. Clin. Can. 53, 5-26 (2003).
3. Goodfellow PN, Lovell-Badge R: SRY and sex determination in mammals. Annu. Rev. Genet. 27, 71-92 (1993).
4. Jost A: Recherches sue la differentiation sexulle de l'embryonde lapen. Arch. Anat. Microsc. Morphol. Exp. 8, 379-418 (1947).
5. Price JM, Donahoe PK, Ito Y, Hendren WH 3rd: Programmed cell death in the Müllerian duct induced by Müllerian Inhibiting Substance. Am. J. Anat. 149, 353-375 (1977).
6. Price JM, Donahoe PK, Ito Y: Involution of the female Müllerian duct of the fetal rat in the organ-culture assay for the detection of Müllerian Inhibiting Substance. Am. J. Anat. 156, 265-284 (1979).
7. Trelstad RL, Hayashi A, Hayashi K, Donahoe PK: The epithelial-mesenchymal interface of the male Müllerian duct: loss of basement membrane integrity and ductal regression. Dev. Biol. 92, 27-40 (1982).
8. Hayashi A, Donahoe PK, Budzik GP, Trelstad RL: Periductal and matrix glycosamino-glycans in rat Müllerian duct development and regression. Dev. Biol. 92, 16-26 (1982).
9. Ikawa H, Trelstad RL, Hutson JM, Manganaro TF, Donahoe PK: Changing patterns of fibronectin, laminin, type IV collagen, and a basement membrane proteoglycan during rat Müllerian duct regression. Dev. Biol. 102, 260-263 (1984).
10. Dyche WJ: A comparative study of the differentiation and involution of the Müllerian duct and Wolffian duct in the male and female fetal mouse. J. Morphol. 162, 175-209 (1979).
11. Picon R: Action du testicule foetal sur le développement in vitro des canaux de Müller chez le rat. Arch. Anat. Microsc. Morph. Exp. 58, 1-19 (1969).
12. Donahoe PK, Ito Y, Marfatia S, Hendren WH 3rd: The production of Müllerian Inhibiting Substance by the fetal, neonatal and adult rat. Biol. Reprod. 15, 329-334 (1976).
13. Josso N: In vitro synthesis of Müllerian inhibiting hormone by seminiferous tubules isolated from the calf fetal testis. Endocrinology 93, 829-834 (1973).
14. Blanchard MG, Josso N: Source of the anti-Müllerian hormone synthesized by the fetal testis: Müllerian-inhibiting activity of fetal bovine Sertoli cells in tissue culture. Pediatr. Res. 8, 968-971 (1974).
15. Donahoe PK, Ito Y, Price JM, Hendren WH: Müllerian Inhibiting Substance activity in bovine fetal, newborn, and prepubertal testes. Biol. Reprod. 16, 238-243 (1977).
16. Josso N: Permeability of membranes to the Müllerian Inhibiting Substance synthesized by the human fetal testis. J. Clin. Endocrinol. Metab. 34, 265-270 (1972).
17. Donahoe PK, Ito Y, Morikawa Y, Hendren WH 3rd: Müllerian Inhibiting Substance in human testes after birth. J. Pediatr. Surg. 12, 323-330 (1977).
18. Hutson J, Ikawa H, Donahoe PK: The ontogeny of Müllerian Inhibiting Substance in the gonads of the chicken. J. Pediatr. Surg. 16(6), 822-827 (1981).
19. Austin HB: Extended production of the Müllerian duct regressor in the American alligator. Gen. Comp. Endocrinol. 96(1), 122-128 (1994).
20. Shen WH, Moore CCD, Ikeda Y, Parker KL, Ingraham HA: Nuclear receptor steroidogenic factor 1 regulates the Müllerian Inhibiting Substance gene: a link to the sex determination cascade. Cell 77, 651-661 (1994). .
21. Giuili G, Shen WH, Ingraham HA: The nuclear receptor SF-1 mediates sexually dimorphic expression of Müllerian Inhibiting Substance, in vivo. Development 124, 1799-1807 (1997).
22. Arango NA, Lovell-Badge R, Behringer RR: Targeted mutagenesis of the endogenous mouse Mis gene promoter: in vivo definition of genetic pathways of vertebrate sexual development. Cell 99, 409-419 (1999).
23. Hossain A, Saunders GF: Role of Wilms tumor 1 (WT1) in the transcriptional regulation of the Müllerian Inhibiting Substance promoter. Biol. Reprod. 69, 1808-1814 (2003).
24. Nachtigal MW, Hirokawa Y, Enyeart-Van Houten DL, Flanagan JN, Hammer GD, Ingraham HA: Wilms' tumor 1 and DAX-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 93, 445-454 (1998).
25. Tremblay JJ, Viger RS: Nuclear receptor Dax-1 represses the transcriptional cooperation between GATA-4 and SF-1 in Sertoli cells. Biol. Reprod. 64, 1191-1199 (2001).
26. Kim JH, Seibel MM, MacLaughlin DT et al.: The inhibitory effects of Müllerian Inhibiting Substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells. J. Clin. Endocrinol. Metab. 75, 911-917 (1992).
27. di Clemente N, Ghaffari S, Pepinsky RB et al.: A quantitative and interspecific test for biological activity of anti-Müllerian hormone: the fetal ovary aromatase assay. Development 114, 721-727 (1992).
28. Rouiller-Fabre V, Carmona S, Merhi RA, Cate R, Habert R, Vigier B: Effect of anti-Müllerian hormone on Sertoli and Leydig cell functions in fetal and immature rats. Endocrinology 139, 1213-1220 (1998).
29. Racine C, Rey R, Forest MG et al.: Receptors for anti-Müllerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. Proc. Natl Acad. Sci. USA 95, 594-599 (1998).
30. Teixeira J, Fynn-Thompson E, Payne A, Donahoe PK: Müllerian Inhibiting Substance regulates androgen synthesis at the transcriptional level. Endocrinology 140, 4732-4738 (1999).
31. Laurich VM, Trbovich AM, O'Neill FH et al.: Müllerian Inhibiting Substance blocks the protein kinase A-induced expression of cytochrome P450 17a-hydroxylase/C17-20 lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation. Endocrinology 143, 3351-3360 (2002).
32. Rey R, Lordereau-Richard I, Carel JC et al.: Anti-Müllerian hormone and testosterone serum levels are inversely during normal and precocious pubertal development. J. Clin. Endocrinol. Metab. 77, 1220-1226 (1993).
33. Bezard J, Vigier B, Tran D, Mauleon P, Josso N: Immunocytochemical study of anti-Müllerian hormone in sheep ovarian follicles during fetal and post-natal development. J. Reprod. Fertil. 80, 509-516 (1987).
34. Munsterberg A, Lovell-Badge R: Expression of the mouse anti-Müllerian hormone gene suggests a role in both male and female sexual differentiation. Development 113, 613-624 (1991).
35. Lee MM, Donahoe PK, Hasegawa T et al.: Müllerian Inhibiting Substance in humans: normal levels from infancy to adulthood. J. Clin. Endocrinol. Metab. 8, 571-576 (1996).
36. Hudson PL, Dougas I, Donahoe PK et al.: An immunoassay to detect human Müllerian Inhibiting Substance in males and females during normal development. J. Clin. Endocrinol. Metab. 70, 16-22 (1990).
37. Josso N, Legeai L, Forest MG, Chaussain JL, Brauner R: An enzyme linked immunoassay for anti-Müllerian hormone: a new tool for the evaluation of testicular function in infants and children. J. Clin. Endocrinol. Metab. 70, 23-27 (1990).
38. Baker ML, Metcalfe SA, Hutson JM: Serum levels of Müllerian Inhibiting Substance in boys from birth to 18, as determined by enzyme immunoassay. J. Clin. Endocrinol. Metab. 70, 11-15 (1990).
39. Lee MM, Donahoe PK, Silverman BL et al.: Müllerian Inhibiting Substance in the evaluation of children with nonpalpable gonads. N. Engl. J. Med. 336, 1480-1486 (1997).
40. van Rooij IA, Broekmans FJ, te Velde ER et al.: Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum. Reprod. 17, 3065-3071 (2002).
41. Silberstein T, MacLaughlin DT, Shai I et al.: Müllerian Inhibiting Substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum. Reprod. 21, 159-163 (2006).
42. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM: Early follicular serum Müllerian Inhibiting Substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil. Steril. 77, 468-471 (2002).
43. Muttukrishna S, Suharjono H, McGarrigle H, Sathanandan M: Inhibin B and anti- Müllerian hormone: markers of ovarian response in IVF/ICSI patients? Brit J. Obstet. Gynaecol. 111, 1248-1253 (2004).
44. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Barcie P: Serum antiMüllerian hormone/Müllerian Inhibiting Substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil. Steril. 82, 1323-1329 (2004).
45. Penarrubia J, Fabregues F, Manau D et al.: Basal and stimulation day 5 anti-Müllerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum. Reprod. 20, 915-922 (2005).
46. Eldar-Geva T, Ben-Chetrit A, Spitz IM et al.: Dynamic assays of inhibin B, anti-Müllerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum. Reprod. 20, 3178-3183 (2005).
47. La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS; the ESHRE Special Interest Group for Reproductive Endocrinology: AMH round table: anti-Müllerian hormone (AMH): what do we still need to know? Hum. Reprod. 24(9), 2264-2275 (2009).
48. Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS: Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod. Biol. Endocrinol. 7(1), 100 (2009).
49. La Marca A, Sighinolfi G, Radi D et al.: Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum. Reprod. Update 16(2), 113-130 (2010).
50. Fallat ME, Siow Y, Marra M, Cook C, Carrillo A: Müllerian Inhibiting Substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil. Steril. 67, 962-965 (1997).
51. Gustafson ML, Lee MM, Scully RE et al.: Müllerian Inhibiting Substance as a marker for ovarian sex-cord tumor. N. Engl. J. Med. 326, 466-471 (1992).
52. Gustafson ML, Lee MM, Asmundson L, MacLaughlin DT, Donahoe PK: Müllerian Inhibiting Substance in the diagnosis and management of intersex and gonadal abnormalities. J. Pediatr. Surg. 28, 439-444 (1993).
53. Chang HL, Pahlavan N, Halpern EF, MacLaughlin DT: Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol. Oncol. 114(1), 57-60 (2009).
54. Dutertre M, Gouedard L, Xavier F et al.: Ovarian granulosa cell tumors express a functional membrane receptor for anti- Müllerian hormone in transgenic mice. Endocrinology 142, 4040-4046 (2001).
55. La Marca A, Volpe A: The Anti-Müllerian hormone and ovarian cancer. Hum. Reprod. Update 13, 265-273 (2007).
56. Geerts I, Vergote I, Neven P, Billen J: The role of inhibins B and anti-Müllerian hormone for diagnosis and follow-up of granulosa cell tumors. Int. J. Gynecol. Cancer 19(5), 847-855 (2009).
57. Ueno S, Manganaro TF, Donahoe PK: Human recombinant Müllerian Inhibiting Substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro. Endocrinology 123, 1652-1659 (1988).
58. Durlinger AL, Kramer P, Karel B et al.: Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 140, 5789-5796 (1999).
59. Seifer DB, MacLaughlin DT, Penzias AS et al.: Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid Müllerian Inhibiting Substance and androgen content. J. Clin. Endocrinol. Metab. 76, 711-714 (1993).
60. Trbovich AM, Sluss PM, Laurich VM et al.: Müllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents. Proc. Natl Acad. Sci. USA 98, 3393-3397 (2001).
61. Lee MM, Seah CC, Masiakos PT et al.: Müllerian Inhibiting Substance type II receptor expression and function in purified rat Leydig cells. Endocrinology 140, 2819-2827 (1999).
62. Baarends WM, Hoogerbrugge JW, Post M et al.: Anit-Müllerian hormone and anti-Müllerian hormone type II receptor messenger ribonucleic acid expression during postnatal testis development and in the adult testis of the rat. Endocrinology 136, 5614-5622 (1995).
63. Bedecarrats GY, O'Neill FH, Norwitz ER, Kaiser UB, Teixeira J: Regulation of gonadotropin gene expression by Müllerian Inhibiting Substance. Proc. Natl Acad. Sci. USA 100, 9348-9353 (2003).
64. Lebeurrier N, Launay S, Macrez R et al.: Anti-Müllerian-hormone- dependent regulation of the brain serine-protease inhibitor neuroserpin. J. Cell Sci. 121(Pt 20), 3357-3365 (2008).
65. Wang PY, Koishi K, McGeachie AB et al.: Müllerian Inhibiting Substance acts as a motor neuron survival factor in vitro. Proc. Natl Acad. Sci. USA 102, 16421-16425 (2005).
66. Segev DL, Hoshiya Y, Hoshiya M et al.: Müllerian Inhibiting Substance regulates NF-kB signaling in the prostate in vitro and in vivo. Proc. Natl Acad. Sci. USA 99, 239-244 (2002).
67. Hoshiya Y, Gupta V, Segev DL et al.: Müllerian substance induces NFkB signaling in breast and prostate cancer cells. Mol. Cell. Endocrinol. 211, 43-49 (2003).
68. Segev DL, Hoshiya Y, Stephen AE et al.: Müllerian Inhibiting Substance regulates NFkB signaling and growth of mammary epithelial cells in vivo. J. Biol. Chem. 276, 26799-26806 (2001).
69. Hoshiya Y, Gupta V, Kawakubo H et al. MIS Promotes INF-g-induced gene expression and apoptosis in breast cancer cells. J. Biol. Chem. 278, 51703-51712 (2003).
70. Picard JY, Josso N: Anti-Müllerian hormone: estimation of molecular weight by gel filtration. Biomedicine 25, 147-150 (1976).
71. Picard JY, Josso N: Purification of testicular anti-Müllerian hormone allowing direct visualization of the pure glycoprotein and determination of yield and purification factor. Mol. Cell. Endocrinol. 34, 23-119 (1984).
72. Swann DA, Donahoe PK, Ito Y, Morikawa Y, Hendren WH: Extraction of Müllerian Inhibiting Substance from newborn calf testis. Dev. Biol. 69, 73-84 (1979).
73. Budzik GP, Swann DA, Hayashi A, Donahoe PK: Enhanced purification of Müllerian Inhibiting Substance by lectin affinity chromatography. Cell 21, 909-915 (1980).
74. Budzik GP, Powell SM, Kamagata S, Donahoe PK: Müllerian Inhibiting Substance fractionation by dye affinity chromatography. Cell 34, 307-314 (1983).
75. Cate RL, Mattaliano RJ, Hession C et al.: Isolation of the bovine and human genes for Müllerian Inhibiting Substance and expression of the human gene in animal cells. Cell 45, 685-698 (1986).
76. Picard JY, Benarous R, Guerrier D, Josso N, Kahn A: Cloning and expression of cDNA for anti-Müllerian hormone. Proc. Natl Acad. Sci. USA 83, 5464-5468 (1986).
77. Josso N, Forest MG, Picard JY: Müllerian inhibiting activity of calf fetal testis: relationship to testosterone and protein synthesis. Biol. Reprod. 13, 163-167 (1975).
78. Vigier B, Picard JY, Josso N: A monoclonal antibody against bovine anti-Müllerian hormone. Endocrinology 110, 131-137 (1982).
79. Shima H, Donahoe PK, Budzik GP, Kamagata S, Hudson P, Mudgett-Hunter M: Production of monoclonal antibodies for affinity purification of bovine Müllerian Inhibiting Substance activity. Hybridoma 3, 201-214 (1984).
80. Cohen-Haguenauer O, Pcard JY, Mattei MG et al.: Mapping of the gene for antiMüllerian hormone to the short arm of human chromosome 19. Cytogenet. Cell Genet. 44, 2-6 (1987).
81. Pepinsky RB, Sinclair LK, Chow EP et al.: Proteolytic processing of Müllerian Inhibiting Substance produces a transforming growth factor-b-like fragment. J. Biol. Chem. 263, 18961-18965 (1988).
82. Nachtigal MW, Ingraham HA: Bioactivation of Müllerian Inhibiting Substance during gonadal development by a kex2/subtilisin-like endoprotease. Proc. Natl Acad. Sci. USA 93, 7711-7716 (1996).
83. MacLaughlin DT, Hudson PL, Graciano AL et al.: Müllerian duct regression and antiproliferative bioactivities of Müllerian Inhibiting Substance reside in its carboxy-terminal domain. Endocrinology 131, 291-296 (1992).
84. Wilson CA, di Clemente N, Ehrenfels C et al.: Müllerian Inhibiting Substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-b superfamily: Mol. Endocrinology 7, 247-257 (1993).
85. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB: Recombinant latent transforming growth factor b 1 has a longer plasma half-life in rats than active transforming growth factor b 1, and a different tissue distribution. J. Clin. Invest. 86, 1976-1984 (1990).
86. Ragin RC, Donahoe PK, Kenneally MK, Ahmad M, MacLaughlin DT: Human Müllerian Inhibiting Substance: enhanced purification imparts biochemical stability and restores antiproliferative effects. Protein Expr. Purif. 3, 236-245 (1992).
87. Lorenzo HK, Teixeira J, Pahlavan N, Laurich VM, Donahoe PK, MacLaughlin DT: New approaches for high-yield purification of Müllerian Inhibiting Substance improve its bioactivity. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 766, 89-98 (2002).
88. Baarends WM, van Helmond JM, Post M et al.: A novel member of the transmembrane serine /threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the Müllerian duct. Development 120, 189-197 (1994).
89. di Clemente N, Wilson C, Faure E et al.: Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone. Mol. Endocrinol. 8, 1006-1020 (1994).
90. Teixeira J, He WW, Shah PC et al.: Developmental expression of a candidate Müllerian Inhibiting Substance type II receptor. Endocrinology 137, 160-165 (1996).
91. Mishina Y, Tizard R, Deng JM et al.: Sequence, genomic organization and chromosomal location of the mouse Müllerian Inhibiting Substance type II receptor gene. Biochem. Res. Commun. 237, 741-746 (1997).
92. Imbeaud S, Faure E, Lamarre I et al.: Insensitivity to anti-Müllerian hormone due to a mutation in the human anti-Müllerian hormone receptor. Nat Genet. 11, 382-388 (1995).
93. Tsuji M, Shima H, Yonemura CY, Brody J, Donahoe PK, Cunha GR: Effect of human recombinant Müllerian Inhibiting Substance on isolated epithelial and mesenchymal cells during Müllerian duct regression in the rat. Endocrinology 131, 1481-1488 (1992).
94. Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK: Endometrial cancer is a receptor mediated target for Müllerian Inhibiting Substance. Proc. Natl Acad. Sci. USA 102, 111-116 (2005); erratum in: Proc. Natl Acad. Sci. USA 102, 6513 (2005).
95. Gupta V, Carey JL, Kawakubo H et al.: Müllerian Inhibiting Substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc. Natl Acad. Sci. USA 102, 3219-3224 (2005).
96. Josso N, Belville C, di Clemente N, Picard YP: AMH and AMH receptor defects in persistent Müllerian duct syndrome. Hum. Reprod. Update 11, 351-356 (2005).
97. Hoshiya M, Christian B, Cromie W, Zhan Y, MacLaughlin DT, Donahoe PK: Persistent Müllerian duct syndrome with a deletion and a novel splicing mutation in the MIS type II receptor. Birth Def. Res. 67, 868-874 (2003).
98. Belville C, van Vlijmen H, Ehrenfels C et al.: Mutations of the anti-Müllerian hormone gene in patients with persistent Müllerian duct syndrome: biosynthesis, secretion and processing of the abnormal proteins and analysis using a three-dimensional model. Mol. Endocrinol. 18, 708-721 (2004).
99. Gouedard L, Chen YG, Thevenet L et al.: Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor. J. Biol. Chem. 275, 27973-27978 (2000).
100. Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP, Inraham HA: The serine/threonine transmembrane receptor ALK2 mediates Müllerian Inhibiting Substance signaling. Mol. Endocrinol. 15, 936-945 (2001).
101. Jamin S, Arango NA, Mishina Y et al.: Requirement of Bmpr1a for Müllerian duct regression during male sexual development. Nat. Genet. 32(3), 408-410 (2002).
102. Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, Donahoe PK: Müllerian Inhibiting Substance signaling uses a BMP-like pathway mediated by ALK2 and induces Smad6 expression. Mol. Endocrinol. 15, 946-959 (2001).
103. Scully RE: Ovarian tumors. A review. Am. J. Pathol. 87, 686-720 (1977).
104. Donahoe PK, Swann DA, Hayashi A, Sullivan MD: Müllerian duct regression in the embryo is correlated with cytotoxic activity against a human ovarian cancer. Science 205, 913-915 (1979).
105. Masiakos PT, MacLaughlin DT, Maheswaran S et al.: Human ovarian cancer, cell lines and primary ascites cells express the human MIS type II receptor, bind, and are responsive to MIS. Clin. Can. Res. 5, 488-499 (1999).
106. Berkenblit A, Cannistra SA: Advances in the management of epithelial ovarian cancer. J. Reprod. Med. 50, 426-438 (2005).
107. Fuller AF Jr, Guy SR, Budzik GP, Donahoe PK: Müllerian Inhibiting Substance inhibits colony growth of a human ovarian cancer cell line. J. Clin. Endocrinol. Metab. 54, 1051-1055 (1982).
108. Donahoe PK, Fuller AF Jr, Scully RE, Guy SR, Budzik GP: Müllerian Inhibiting Substance inhibits growth of a human ovarian cancer in nude mice. Ann Surg. 194, 472-480 (1981).
109. Fuller AF, Jr, Krane IM, Budzik GP, Donahoe PK: Müllerian Inhibiting Substance reduction of colony growth of human gynecologic cancers in a stem cell assay. Gynecol. Oncol 22, 135-148 (1985).
110. Chin T, Parry RL, Donahoe PK: Human Müllerian Inhibiting Substance inhibits tumor growth in vitro and in vivo. Can. Res. 51, 2101-2106 (1991).
111. Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT: Highly purified Müllerian Inhibiting Substance inhibits ovarian cancer in vivo. Clin. Can. Res. 8, 2640-2646 (2002).
112. Wallen JW, Cate RL, Kiefer DM et al.: Minimal antiproliferative effect of recombinant Müllerian Inhibiting Substance on gynecological tumor cell lines and tumor explants. Cancer Res. 49, 2005-2011 (1989).
113. Bakkum-Gamez JN, Aletti G, Lewis KA et al.: Müllerian Inhibiting Substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol. Oncol. 108(1), 141-148 (2008).
114. Song JY, Chen KY, Kim SY et al.: The expression of Müllerian Inhibiting Substance/anti-Müllerian hormone type II Receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia. Int. J. Oncol. 34(6), 1583-1591 (2009).
115. Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK: Müllerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci USA 100, 15601-15606 (2003).
116. Connolly DC, Bao R, Nikitin AY et al.: Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Can. Res. 63, 1389-1397 (2003).
117. Pieretti-Vanmarcke R, Donahoe PK, Szotek P et al.: Recombinant human Müllerian Inhibiting Substance inhibits long term growth of MISRII-directed transgenic mouse ovarian cancers in vivo. Clin. Can. Res. 12(5), 1593-1598 (2006).
118. Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA et al.: Müllerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc. Natl Acad. Sci. USA 103(46), 17426-17431 (2006).
119. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT et al.: Ovarian cancer side population defines cells with stem cell-like characteristics and Müllerian Inhibiting Substance responsiveness. Proc. Natl Acad. Sci. USA 103(30), 11154-11159 (2006).
120. Sovak MA, Bellas RE, Kim DW et al.: Aberrant nuclear factor-kB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100, 2952-2960 (1997).
121. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Sledge GW: Constitutive activation of NF-kB during progression of breast cancer to hormone-independent growth. Mol. Cell Biol. 17, 3629-3639 (1997).
122. Dorgan JF, Stanczyk FZ, Egleston BL et al.: Prospective case-control study of serum Müllerian Inhibiting Substance and breast cancer risk. J. Natl Cancer Inst. 101(21), 1501-1509 (2009).